Michelle Gilson Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 1 week ago
Michelle Gilson has an estimated net worth of at least $19.8 million*, as of April 22, 2026. They own 0 shares of ACLX stock. They have sold 167,208 shares of ACLX stock since 2021, for an estimated $12.1 million.
Michelle Gilson $ACLX SEC Form 4 Insider Trading
Michelle Gilson has filed a total of 37 insider trades in $ACLX since 2021. Their most recent trade was a sale of 11,219 shares, made on Feb 25, 2026. Their largest trade was a sale of 12,326 shares, made on Jun 26, 2024. We estimate that they now own 0 shares of $ACLX, worth an estimated $7.7 million.
Insider Trading at $ACLX
There have been a total of 188 insider trades reported at $ACLX since 2021, with 6.1 million shares purchased and 4.1 million shares sold. The most active insider traders in $ACLX stock have been Christopher Heery, Michelle Gilson, and Christopher Heery. The most recent trade was a sale of 89,916 shares reported by Rami Elghandour (SEE REMARKS), made on Feb 27, 2026.
History of Insider Stock Trades by Michelle Gilson
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
ACLX
|
Sale | 11,219 | Feb 25, 2026 | Feb. 25, 2026, 8:51 p.m. |
ACLX
|
Sale | 100 | Feb 19, 2026 | Feb. 19, 2026, 7:26 p.m. |
ACLX
|
Sale | 5,405 | Feb 19, 2026 | Feb. 19, 2026, 7:26 p.m. |
ACLX
|
Sale | 2,879 | Feb 19, 2026 | Feb. 19, 2026, 7:26 p.m. |
ACLX
|
Sale | 7,141 | Feb 17, 2026 | Feb. 18, 2026, 6:19 p.m. |
ACLX
|
Sale | 4,150 | Feb 17, 2026 | Feb. 18, 2026, 6:19 p.m. |
ACLX
|
Sale | 5,364 | Oct 15, 2025 | Oct. 15, 2025, 7:28 p.m. |
ACLX
|
Sale | 4,882 | Oct 03, 2025 | Oct. 6, 2025, 7:21 p.m. |
ACLX
|
Sale | 1,064 | Oct 06, 2025 | Oct. 6, 2025, 7:21 p.m. |
ACLX
|
Sale | 3,786 | May 27, 2025 | May 28, 2025, 8:18 p.m. |
ACLX
|
Sale | 8,449 | May 27, 2025 | May 28, 2025, 8:18 p.m. |
ACLX
|
Sale | 3,128 | Jan 07, 2025 | Jan. 10, 2025, 10:36 p.m. |
ACLX
|
Sale | 3,997 | Jan 08, 2025 | Jan. 10, 2025, 10:36 p.m. |
ACLX
|
Sale | 1,546 | Jan 07, 2025 | Jan. 10, 2025, 10:36 p.m. |
ACLX
|
Sale | 2,327 | Jan 07, 2025 | Jan. 10, 2025, 10:36 p.m. |
ACLX
|
Sale | 2,251 | Jan 07, 2025 | Jan. 10, 2025, 10:36 p.m. |
ACLX
|
Sale | 4,760 | Jan 07, 2025 | Jan. 10, 2025, 10:36 p.m. |
ACLX
|
Sale | 5,102 | Jan 06, 2025 | Jan. 6, 2025, 10:54 p.m. |
ACLX
|
Sale | 5,502 | Jan 03, 2025 | Jan. 6, 2025, 10:54 p.m. |
ACLX
|
Sale | 500 | Nov 15, 2024 | Nov. 19, 2024, 7:46 p.m. |
ACLX
|
Sale | 1,061 | Nov 15, 2024 | Nov. 19, 2024, 7:46 p.m. |
ACLX
|
Sale | 100 | Nov 15, 2024 | Nov. 19, 2024, 7:46 p.m. |
ACLX
|
Sale | 100 | Nov 15, 2024 | Nov. 19, 2024, 7:46 p.m. |
ACLX
|
Sale | 801 | Nov 08, 2024 | Nov. 12, 2024, 9:31 p.m. |
ACLX
|
Sale | 1,853 | Nov 08, 2024 | Nov. 12, 2024, 9:31 p.m. |
ACLX
|
Sale | 9,700 | Nov 08, 2024 | Nov. 12, 2024, 9:31 p.m. |
ACLX
|
Sale | 8,726 | Sep 17, 2024 | Sept. 17, 2024, 8:54 p.m. |
ACLX
|
Sale | 6,274 | Sep 17, 2024 | Sept. 17, 2024, 8:54 p.m. |
ACLX
|
Sale | 551 | Jun 26, 2024 | June 28, 2024, 4:06 p.m. |
ACLX
|
Sale | 12,326 | Jun 26, 2024 | June 28, 2024, 4:06 p.m. |
ACLX
|
Sale | 12,121 | May 24, 2024 | May 24, 2024, 8:16 p.m. |
ACLX
|
Sale | 3,782 | Mar 18, 2024 | March 18, 2024, 8:49 p.m. |
ACLX
|
Sale | 3,043 | Mar 18, 2024 | March 18, 2024, 8:49 p.m. |
ACLX
|
Sale | 8,514 | Jan 04, 2024 | Jan. 8, 2024, 5:04 p.m. |
ACLX
|
Sale | 8,554 | May 24, 2023 | May 25, 2023, 8:21 p.m. |
ACLX
|
Sale | 6,000 | May 25, 2023 | May 25, 2023, 8:21 p.m. |
ACLX
|
Sale | 150 | May 24, 2023 | May 25, 2023, 8:21 p.m. |
$ACLX Executives and Stock Owners with Insider Trades
-
Christopher Heery, CHIEF MEDICAL OFFICER
-
Michelle Gilson, CHIEF FINANCIAL OFFICER
-
Christopher Heery, Chief Medical Officer
-
Rami Elghandour, SEE REMARKS
-
Michelle Gilson, Chief Financial Officer
-
Rami Elghandour, See Remarks
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.